Afatinib dimaleateProduct ingredient for Afatinib

Afatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif ^Label. For oral use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test ⁴. Gilotrif (afatinib) is the first FDA-approved oncology product from Boehringer Ingelheim ⁴.